Want to join the conversation?
$CREE said 4Q16 results were in the middle of the company's target range. LED products continued to execute well, despite the challenging competitive environment. Lighting products revenue grew 6% sequentially to $198MM, which was in line with $CREE's targets and commercial lighting revenue improved from 3Q16 with double-digit growth.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.